RituximabSerum sickness following off-label use: 5 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1776卷 / 1期

关键词：

D O I：

10.1007/s40278-019-70556-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：398 / 398

相关论文

共 50 条

[41] TocilizumabVarious toxicities following off-label use: 4 case reports
Reactions Weekly, 2023, 1973 (1) : 264 - 264
[42] RuxolitinibVarious infections following off-label use: 6 case reports
Reactions Weekly, 2019, 1739 (1) : 227 - 227
[43] AsciminibLack of efficacy following off-label use: 3 case reports
Reactions Weekly, 2023, 1982 (1) : 73 - 73
[44] FavipiravirLack of efficacy following off-label use: 6 case reports
Reactions Weekly, 2022, 1928 (1) : 178 - 178
[45] AmisulprideVarious toxicities following off-label use: 6 case reports
Reactions Weekly, 2019, 1766 (1) : 22 - 23
[46] TriamcinoloneOcular hypertension following off-label use: 2 case reports
Reactions Weekly, 2022, 1917 (1) : 567 - 567
[47] AcetazolamideWorsening acidosis following an off-label use: 2 case reports
Reactions Weekly, 2020, 1821 (1) : 14 - 14
[48] TemsirolimusVarious toxicities following off-label use: 8 case reports
Reactions Weekly, 2021, 1869 (1) : 328 - 328
[49] DaratumumabLack of efficacy following off-label use: 2 case reports
Reactions Weekly, 2022, 1925 (1) : 204 - 204
[50] MemantineVarious toxicities following off-label use: 8 case reports
Reactions Weekly, 2021, 1867 (1) : 246 - 246

← 1 2 3 4 5 →